AstraZeneca in $1.77B China CSPC kidney-disease collaboration
AstraZeneca's $1.77B CSPC kidney-disease collaboration drives 3.89% gain
- AZN announced deal with China's CSPC Pharma on July 2 for siRNA candidates targeting kidney diseases
- Up to $1.77 billion deal gives AZN option for global rights to one preclinical candidate and ex-China rights to another
- Builds on prior CSPC partnerships; aligns with AZN's China R&D expansion and pipeline in high-unmet-need CKD area
- Positive news coincides with Abbisko Therapeutics collab on oral PD-L1 inhibitor + TAGRISSO for NSCLC
- Stock rebounded from ~3% decline on July 1 close; traders and X buzz cited pipeline momentum as catalyst
- Move occurred during regular trading on NYSE; no earnings (Q2 due July 27) or other macro drivers noted
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.